Proteolytic Processing of Familial British Dementia-associated BRI Variants
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; none of the 32 sources its claims cite is checked for support yet.
Abstract
Different mutations in the BRI(2) gene cause rare neurodegenerative conditions, termed familial British dementia (FBD) and familial Danish dementia (FDD). The mutant genes encode BRI-L and BRI-D, the precursors of fibrillogenic ABri and ADan peptides, respectively. We previously reported that furin processes both BRI-L and its wild type counterpart, BRI, resulting in the secretion of C-terminal peptides; elevated levels of peptides were generated from BRI-L. In the present study, we show that inducible expression of alpha1-antitrypsin Portland, a furin inhibitor, inhibits the endoproteolysis of BRI and BRI-L in a dose-dependent manner. Moreover, comparison of the activities of several proprotein convertases reveals that furin is most efficient in endoproteolysis of BRI and BRI-L; PACE4, PC6A, PC6B, and LPC show much lower activities. Interestingly, LPC also exhibits enhanced cleavage of BRI-L compared with BRI. Finally, we demonstrate that BRI-D is also processed by furin and, like BRI-L, the cleavage of BRI-D is more efficient than that of BRI. Interestingly, while the ABri peptide is detected both intracellularly and in the medium, the ADan peptide accumulates predominantly in intracellular compartments. We propose that intracellular accumulation of amyloidogenic ADan or ABri peptides results in the neuronal damage leading to FDD and FBD, respectively.
Overview
CoChat Summary
TL;DR
Furin is the major proprotein convertase processing wild-type BRI and the FBD/FDD-associated variants BRI-L and BRI-D, with BRI-L and BRI-D cleaved more efficiently than BRI. Although ABri is secreted, ADan accumulates predominantly intracellularly, suggesting intracellular amyloidogenic peptide accumulation contributes to FBD/FDD neuronal damage.
Key findings
- Inducible expression of the furin inhibitor α1-PDX inhibited endoproteolysis of BRI and BRI-L in a dose-dependent manner; full-length BRI-L accumulated as inhibitor levels increased. α1-PDX is described as a relatively specific furin inhibitor with an IC50 of 0.6 nM for furin.
- In furin-defective RPE.40 cells, furin was most efficient at restoring BRI and BRI-L cleavage; PC6A and LPC processed BRI at ~20% of furin’s efficiency, while PACE4 and PC6B failed to proteolyse BRI and BRI-L. LPC also showed enhanced cleavage of BRI-L compared with BRI, whereas PC6A cleaved wild-type and mutant molecules with similar efficiency.
- BRI-D was also processed by furin, and like BRI-L, its furin cleavage was more efficient than that of wild-type BRI. Intracellular levels of both ABri and ADan peptides were elevated by ~4-fold compared with wild-type peptides, but ADan accumulated predominantly intracellularly; secreted ADan was much lower and did not increase even after an 8-h chase, whereas BRI-L cells secreted higher levels of ABri than wild-type BRI cells.
Methods
- Cell models: mouse neuroblastoma N2a, furin-defective RPE.40, HEK293, CHO-K1, and EcR293 cells were transiently or stably transfected with epitope-tagged BRI, BRI-L, BRI-D, proprotein convertases (furin, PACE4, PC6A, PC6B, LPC), and/or inducible FLAG-tagged α1-PDX.
- Metabolic labeling and analysis: cells were labeled with [35S]cysteine, with pulse-chase experiments using a 2-h pulse and chases at 2, 4, 6, or 8 h; cell lysates and conditioned medium were immunoprecipitated with αBRI-NT or CT11 antibodies, separated by SDS-PAGE, and quantified by Phosphorimager.
- Main comparisons: effects of α1-PDX on BRI/BRI-L processing; relative efficiencies of proprotein convertases against BRI and BRI-L; furin-mediated processing of BRI-D; and intracellular versus secreted levels of ABri and ADan peptides normalized to full-length precursor.
Limitations
- Paper-stated: the authors note it is unclear why ABri and ADan behave so differently in secretion; the mechanisms by which ABri or ADan initiate clinical syndromes are not defined; and transgenic mice overexpressing human BRI-L or BRI-D are needed to define in vivo roles. They also state it is difficult to quantify each protease’s activity in transfected cells and that reasons for PC6A cleaving wild-type and mutant molecules similarly are not presently clear.
- Evident from the text: all processing data come from transfected cell lines and in vitro labeling/immunoprecipitation assays, with no human tissue or in vivo validation presented. The proposed explanation that ADan may aggregate intracellularly and thereby avoid secretion is a hypothesis that the paper says can be tested by structural and biophysical analyses but is not directly tested here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![FIG. 2 Effects of proprotein convertases on BRI processing. A-D , RPE.40 cells transiently transfected with BRI ( A ) or BRI-L ( B ) in combination with different members of proprotein convertase family (furin, PACE4, PC6A, PC6B, or LPC) or APP (for control) were labeled with [ 35 S]cysteine for 2 h. Cell lysates ( upper panels ) and conditioned medium ( lower panels ) were immunoprecipitated with 𝛂 BRI-NT and CT11 antibodies, respectively and analyzed by 10% Tris/glycine ( upper panels ) and 16.5% Tris/Tricine ( lower panels ) SDS-PAGE. The intensity of each band was quantified by Phosphorimager and relative levels of secreted Cterminal peptides normalized to those of full-length molecules were calculated ( C ). The relative level of ABri compared with the wild type C-terminal peptide for each PC is also shown to demonstrate different efficiencies of PCs against BRI and BRI-L ( D ). E , expression of the proprotein convertases was confirmed by immunoprecipitation analyses with respective antibodies. Immunoprecipitated materials were run on 7% SDS-PAGE and visualized by Phosphorimager. In panels A , B , and E , molecular mass markers are in kDa.](https://figures.cochat.ai/paper-figures/5b4440468c7a4a61a72db588e116746f/proteolytic-processing-of-familial-british-dementia-associated-bri-variants-figure-2.png)


![FIG. 5 Kinetic analysis of proteolytic processing of BRI variants. A and B , HEK293 cells transiently transfected with BRI ( lanes 1-5 ), BRI-L ( lanes 6-10 ), or BRI-D ( lanes 11-15 ) cDNAs were pulse-labeled with [ 35 S]cysteine for 2 h and chased for 2, 4, 6, or 8 h. Cell lysates ( A ) or conditioned medium ( B ) were immunoprecipitated with CT11 antibody, and recovered proteins were fractionated by 16.5% Tris/Tricine SDSPAGE. The radioactive bands were visualized by phosphorimaging. Molecular mass markers are in kDa. C-D , the intensity of each band was quantified by Phosphorimager, and relative levels of intracellular ( C ) or secreted ( D ) peptides normalized to the levels of respective fulllength molecules were calculated and expressed as percentages of the value for wild type BRI at the time 0 point.](https://figures.cochat.ai/paper-figures/9140d82e2fa5407f874c024c38b6dfb7/proteolytic-processing-of-familial-british-dementia-associated-bri-variants-figure-5.png)
Verification
Claims the paper makes
0 Valid · 0 Not valid · 19 Not checked · 20 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“phosphorimaging analysis revealed that intracellular levels of both ABri and ADan peptides were elevated by ϳ4 fold compared with wild type peptides”
§ Proteolytic Processing of Familial British Dementia-associated BRI Variants EVIDENCE FOR ENHANCED INTRACELLULAR ACCUMULATION OF AMYLOIDOGENIC PEPTIDES* > Proteolytic Processing of the Danish Variant of BRI-We
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BRI-D is also processed by furin”
- Also stated in: § Proteolytic Processing of the Danish Variant of BRI-We · hedged
“coexpression of BRI-D with furin in RPE.40 cells led to the production and secretion of the ϳ4-kDa ADan peptide”
- Also stated in: § DISCUSSION · plain
“the FDD-associated Danish variant (BRI-D) is processed by furin.”
§ Proteolytic Processing of Familial British Dementia-associated BRI Variants EVIDENCE FOR ENHANCED INTRACELLULAR ACCUMULATION OF AMYLOIDOGENIC PEPTIDES* > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Proteolytic Processing of the Danish Variant of BRI-We · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“like BRI-L, the cleavage of BRI-D is more efficient than that of BRI.”
- Also stated in: § DISCUSSION · plain
“the BRI-D precursor is also subject to enhanced furin-mediated cleavage.”
§ Proteolytic Processing of Familial British Dementia-associated BRI Variants EVIDENCE FOR ENHANCED INTRACELLULAR ACCUMULATION OF AMYLOIDOGENIC PEPTIDES* > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § DISCUSSION · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the level of secreted ADan peptides in the conditioned medium of cells expressing BRI-D was considerably reduced”
- Also stated in: § DISCUSSION · plain
“the level of secreted ADan peptide in the conditioned medium is much lower compared with those of wild type and ABri peptides”
§ Proteolytic Processing of Familial British Dementia-associated BRI Variants EVIDENCE FOR ENHANCED INTRACELLULAR ACCUMULATION OF AMYLOIDOGENIC PEPTIDES* > Proteolytic Processing of the Danish Variant of BRI-We
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § DISCUSSION · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the ADan peptide accumulates predominantly in intracellular compartments.”
- Also stated in: § Proteolytic Processing of the Danish Variant of BRI-We · plain
“most of the ADan peptide remained within intracellular compartments”
- Also stated in: § DISCUSSION · plain
“the ADan peptide largely accumulates in intracellular compartments”
§ Proteolytic Processing of Familial British Dementia-associated BRI Variants EVIDENCE FOR ENHANCED INTRACELLULAR ACCUMULATION OF AMYLOIDOGENIC PEPTIDES* > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Proteolytic Processing of the Danish Variant of BRI-We · plain
17 more claims
Create a free account to see all 39 claims and to verify the 32 references still open.
- It may state two separate claims as one. 13
- The quote only partly states this claim. 1
- Probably not a substantial claim. 4
Citations
Cites
Schägger, H., & von Jagow, G. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90587-2 · Cited by 11,444
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
NAKAYAMA, K. (1997) · Biochemical Journal · doi:10.1042/bj3270625 · Cited by 789
Seidah, N. G., & Chrétien, M. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01909-5 · Cited by 761
Waelter, S., Boeddrich, A., Lurz, R., Scherzinger, E., Lueder, G., Lehrach, H., & Wanker, E. E. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.5.1393 · Cited by 631
SEIDAH, N. G., GASPAR, L., MION, P., MARCINKIEWICZ, M., MBIKAY, M., & CHRÉTIEN, M. (1990) · DNA and Cell Biology · doi:10.1089/dna.1990.9.415 · Cited by 512
A stop-codon mutation in the BRI gene associated with familial British dementia
Vidal, R., Frangione, B., Rostagno, A., Mead, S., Révész, T., Plant, G., & Ghiso, J. (1999) · Nature · doi:10.1038/21637 · Cited by 466
Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis
Molloy, S. S., Anderson, E. D., Jean, F., & Thomas, G. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01382-8 · Cited by 429
Vidal, R., Révész, T., Rostagno, A., Kim, E., Holton, J. L., Bek, T., Bojsen-Møller, M., Braendgaard, H., Plant, G., Ghiso, J., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.080076097 · Cited by 300
Research works printed but not linked: 1
- Seidah, 1992, Mol. Endocrinol., 6, 1559
Cited by
Furin at the cutting edge: From protein traffic to embryogenesis and disease
Thomas, G. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm934 · Cited by 1,216
Curbing activation: proprotein convertases in homeostasis and pathology
Taylor, N. A., Van De Ven, W. J. M., & Creemers, J. W. M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0831rev · Cited by 205
Self-citationRegulated Intramembrane Proteolysis of Bri2 (Itm2b) by ADAM10 and SPPL2a/SPPL2b
Martin, L., Fluhrer, R., Reiss, K., Kremmer, E., Saftig, P., & Haass, C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706661200 · Cited by 155
Kelly, J. W., & Balch, W. E. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200304074 · Cited by 138
General aspects of neurodegeneration
Jellinger, K. A. (2003) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-0643-3_7 · Cited by 126
Metadata
- Authors
- Kim, S.-H., Creemers, J. W. M., Chu, S., Thinakaran, G., & Sisodia, S. S.
- Affiliations
- University of Chicago (US)
- KU Leuven (BE)
- Corresponding author
- Sisodia, Sangram S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-01
- Volume
- 277
- Issue
- 3
- Pages
- 1872-1877
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2039742890
- Cited by
- 63
- References
- 31
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2022: 2 · 2021: 2 · 2020: 2 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 4 · 2014: 4 · 2013: 3 · 2012: 4
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6851 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- University of Oregon
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Keywords
- familial British dementia, familial Danish dementia, furin, proteolytic processing, proprotein convertases, PACE4, LPC, amyloidogenic peptides, neurodegeneration
- MeSH terms
- alpha 1-Antitrypsin, Amyloid, Cell Compartmentation, Dementia, Humans, Hydrolysis, Kinetics, Membrane Glycoproteins, Membrane Proteins, Mutation, Peptide Fragments, Protein Processing, Post-Translational, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.